Medexus Pharmaceuticals (CVE:MDP) Stock Price Down 4.9%

Medexus Pharmaceuticals Inc. (CVE:MDP) traded down 4.9% during mid-day trading on Friday . The company traded as low as C$7.70 and last traded at C$7.75. 40,981 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 68,619 shares. The stock had previously closed at C$8.15.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus reduced their price objective on shares of Medexus Pharmaceuticals from C$2.85 to C$2.35 in a research note on Thursday, February 22nd.

Medexus Pharmaceuticals Trading Down 4.9 %

The stock’s 50 day moving average price is C$7.75 and its 200-day moving average price is C$7.75. The company has a quick ratio of 0.74, a current ratio of 1.19 and a debt-to-equity ratio of 1,174.36. The stock has a market capitalization of C$148.54 million and a PE ratio of -4.28.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older.